Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer-Reference-Cited by-同舟云学术

Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer

Published:2023-09-20 Issue:12 Volume:129 Page:2003-2013
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Shirasawa Masayuki,Yoshida Tatsuya^ORCID,Shiraishi Kouya^ORCID,Goto Naoko,Yagishita Shigehiro,Imabayashi Tatsuya,Matsumoto Yuji,Masuda Ken,Shinno Yuki,Okuma Yusuke^ORCID,Goto Yasushi,Horinouchi Hidehito^ORCID,Yotsukura Masaya,Yoshida Yukihiro,Nakagawa Kazuo,Naoki Katsuhiko,Tsuchida Takaaki,Hamamoto Ryuji^ORCID,Yamamoto Noboru,Motoi Noriko^ORCID,Kohno Takashi,Watanabe Shun-ichi,Ohe Yuichiro

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-023-02427-3.pdf

Reference48 articles.

1. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17:725–37. https://doi.org/10.1038/nrc.2017.87.

2. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9. https://doi.org/10.1056/NEJMoa1809064.

3. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–39. https://doi.org/10.1016/S0140-6736(19)32222-6.

4. Tanaka K, Isse K, Fujihira T, Takenoyama M, Saunders L, Bheddah S, et al. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer. 2018;115:116–20. https://doi.org/10.1016/j.lungcan.2017.11.018.

5. Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019;25:6958–66. https://doi.org/10.1158/1078-0432.Ccr-19-1133.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy;International Immunopharmacology;2024-11

2. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies;Signal Transduction and Targeted Therapy;2024-05-27

3. Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors;Journal of Cancer Research and Clinical Oncology;2024-03-14

4. Promising therapy for neuroendocrine prostate cancer: current status and future directions;Therapeutic Advances in Medical Oncology;2024-01